Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ComboMATCH: Neratinib +/- Palbociclib in HER2+ Solid Tumors
NCT06126276Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2024
- Primary completion
- Feb 2027
- Countries
- 2
01
Overview
A Phase 2 trial of palbociclib in gynecologic cancer, solid tumor, sponsored by National Cancer Institute. Started May 2024; status: recruiting.
02
Drugs
palbociclib
03
Conditions
gynecologic cancersolid tumor
Beyond the preview
Go deeper on NCT06126276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06126276.